Medication error is the most common type of medical error in the United States, injuring approximately 1.3-1.5 million people and accounting for 251,000 preventable deaths per year (asamonitor.pub/2SF59mC; Preventing Medication Errors. 2007; BMJ 2016;353:i2139). Although medication errors in anesthesia are difficult to study, accumulating evidence shows that medication errors in anesthesia occur frequently (Anesthesiology 2016;124:25-34; Br J Anaesth 2018;120:563-70). The Anesthesia Patient Safety Foundation (APSF) has long recognized the need for increased medication safety awareness. There have been numerous articles in the APSF Newsletter and three in-person Consensus Conferences with multiple stakeholders, including anesthesiologists, nurse anesthetists, pharmacists, drug manufacturers, and 503B compounders, dedicated to advancing medication safety (asamonitor.pub/2TnzNB4; asamonitor.pub/3jstN4U).
One of the most highly debated issues with regard to medication errors and the process of medication administration is drug labeling. ASA created a Statement on Labeling of Pharmaceuticals for Use in Anesthesiology in 2004, which was most recently revised in 2020 (asamonitor.pub/3x11FcZ). The rationale for creating this statement was to reduce medication errors by incorporating standards established by ASTM International (formerly the American Society for Testing and Materials) and the International Organization for Standards, as well as recommendations from the Food and Drug Administration and US Pharmacopeia (USP). The statement is targeted to a broad audience, including clinicians, drug manufacturers, 503B compounding facilities, and label and label printer manufacturers, to enhance standardization of labels.
Issues in drug labeling
ASA's Statement on Labeling of Pharmaceuticals for Use in Anesthesiology recommends that the drug's generic name and concentration in units per mL should be the most prominent items displayed on the label of each syringe (Figure 1) (asamonitor.pub/3x11FcZ). In addition, the date, time, and name or initials of the preparer should also be on the label whenever a medication is withdrawn from a vial or ampule into a syringe. The placement of a label on a syringe should be done in a manner where the label may be read while administering the medication and without obscuring the syringe gradations (P&T 2010;35:428-9). Pre-filled syringes are supplied by either drug manufacturers or outsourcing facilities, and the FDA guidance in terms of labeling varies depending on the source (asamonitor.pub/3qErlcX; asamonitor.pub/3AbbeYS).
Having the total amount in the syringe divided by the total volume appear in the prominent position, as frequently seen on vials and prefilled syringes produced by drug manufacturers and some outsourcing facilities (Figure 2), requires an additional mathematical calculation that may lead to a medication error. Having standard labeling practices for all prefilled syringes regardless of source would potentially mitigate medication errors and reduce confusion among anesthesia professionals (asamonitor.pub/3x11FcZ; asamonitor.pub/3qErlcX).
USP Chapter 7 provides the standards for labeling (asamonitor.pub/3qzGWdO). Vials and ampules display the name of the medication and the concentration with the total amount of medication in the container divided by the total volume in the most prominent position, followed in close proximity by the concentration per mL. Exceptions to this practice include when the container volume is less than or equal to one mL or when the prominent expression of total drug content per container would not be effective in preventing medication errors. Examples of exceptions include insulin, which displays the concentration in units per mL, similar to the recommended manner in which syringes are to be labeled (Figure 3), and local anesthetics, which are expressed as a percent and the quantity per total volume, followed in close proximity by the amount per mL (e.g., Lidocaine 1% (100 mg/10 mL) (10mg/mL) (Figure 4).
Medication errors with ratio expressions have resulted in serious adverse events, including death (asamonitor.pub/2UeQnDf). Ratio expressions are confusing to health care providers and have caused 10- to thousand-fold dosing medication errors. In 2017, the FDA required a change in labeling, eliminating ratio expressions for single-entity injectable products, after the USP instituted a new labeling standard in the revision of General Chapter <7> Labeling (asamonitor.pub/2UeQnDf; asamonitor.pub/3dscMnk). Thus, the label for a single vial of epinephrine now reads 1 mg/mL rather than 1:1,000. The elimination of ratios is for single-entity products. Epinephrine in a multi-ingredient formulation combined with local anesthetics may currently continue to be expressed using ratios.
Color coding is a system that uses different colors to indicate a specific meaning. Per the FDA, color coding is reserved for special circumstances, only after human factors testing has been done and feedback received (asamonitor.pub/3dscnBx). In the perioperative setting, color coding is used for syringe labeling to designate drug classes. When color coding is used outside of the OR, errors may still occur in environments where it is not meaningful (asamonitor.pub/3dscnBx; APSF Newsletter;2019:33). Color-coded medication labels help to recognize different medication classes by acting as cues in addition to lettering. As such, color-coded labels may mitigate the extent of a medication error because they help to prevent errors between different drug classes, e.g., neuromuscular blockers and opioids. While they do not help reduce errors between drugs in the same class of medications, e.g., different opioids, the consequences of such same-class medication errors are often going to be less severe than between-class errors. However, the color coding of labels is thought by some to provide a false reassurance of the contents of the syringe that will decrease the chance that the label will be read (APSF Newsletter;2019:33). In addition, for individuals with color vision impairment, the ability to detect certain colors may be affected. Color coding should never serve as a substitute for reading the label.
Reducing medication errors related to labeling
The 2017 European Board of Anesthesiology's updated recommendations for safe medication practice include correct labeling before leaving the hand of the operator, standardizing work surfaces, and the use of pre-filled syringes (Eur J Anaesthesiol 2017;34:4-7). In addition, there is a regulatory requirement from The Joint Commission that all meds must be labeled unless immediately administered and that they must be labeled as soon as they are prepared (asamonitor.pub/3y5vXvh). The application of human factors engineering, focused on eliminating error-prone steps, would further aid in reducing medication errors. Anesthesiologists are in a unique position to apply human factors methods to reduce or mitigate medication errors related to labeling, since they are the physicians responsible for the entire medication delivery process from prescription through preparation and administration.
Labels serve as a safety measure that provides feedback to the health care professional. A study using failure mode and effects analysis identified 19 sub-steps and 68 possible failure modes each time a medication is handled in the perioperative environment (Paediatr Anaesth 2017;27:571-80). Using pre-filled syringes eliminated six sub-steps and 19 possible failure modes from medication preparation (Paediatr Anaesth 2017;27:571-80; asamonitor.pub/3hhYGpN).
At the 2018 APSF Stoelting Conference, one of the recommendations of the Standardization and Innovation Workgroup was to support a request for proposal(s)/grant(s) to develop a standard for labeling of vials and syringes that integrates contributions from human factors experts, graphic designers, and clinicians (asamonitor.pub/2Ok8P7w). Implementing such a standard would help to reduce errors due to look-alike vials. APSF continues to collaborate with organizations dedicated to promoting medication safety. In November 2021, APSF will be a supporter of the Institute for Safe Medication Practices Consensus Conference on Perioperative Medication Safety. We will continue to work collectively with all stakeholders, utilizing appropriate technology to reduce harm and make each subsequent medication administration as safe as possible for our patients.